Amy E. Glasgow

Amy E. Glasgow

Auto-generated profile, based on publicly available information

Amy E. Glasgow

Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2017 in Surgery
Verified
Journal Article
Closed access
DLDanuel V. Laan
Danuel V. Laan
CTCornelius A A. Thiels
Cornelius A A. Thiels
AGAmy Glasgow
Amy Glasgow
KWKevin B. Wise
Kevin B. Wise
GTGeoffrey B. Thompson
Geoffrey B. Thompson
TMTravis J. McKenzie
Travis J. McKenzie

1 December 2018 in Diseases of the Colon & Rectum
Verified
Journal Article
Closed access
NMNicholas Paul McKenna
Nicholas Paul McKenna
EHElizabeth B. Ph.D. Habermann
Elizabeth B. Ph.D. Habermann
AGAmy E. M.H.A. Glasgow
Amy E. M.H.A. Glasgow
EDEric J. Dozois
Eric J. Dozois
ALAmy L. Lightner
Amy L. Lightner
BACKGROUND: Intra-abdominal sepsis complicates <10% of ileocolic resections for Crohn’s disease, but the impact of combination immunosuppression and repeat resection on its development remains unknown. OBJECTIVE: The purpose of this study was to determine risk factors for intra-abdominal sepsis after ileocolic resection, specifically examining the role of combination immunosuppression and repeat intestinal resection. DESIGN: This was a retrospective review of patient records from 2007 to 2017. SETTINGS: The study was conducted at a single-institution IBD tertiary referral center. PATIENTS: Patients with a diagnosis of Crohn’s disease who were undergoing ileocolic resection with primary anastomosis were included. Diverted patients were excluded. MAIN OUTCOME MEASURES: Preoperative and intraoperative variables, including preoperative immunosuppressive regimens and previous intestinal resection, were evaluated as potential risk factors for intra-abdominal sepsis. RESULTS: A total of 621 patients (55% women) underwent ileocolic resection for Crohn’s disease; 393 (63%) were first-time resections. The rate of 30-day intra-abdominal sepsis was 8% (n = 50). On univariate analysis, triple immunosuppression (combination of a corticosteroid, immunomodulator, and biological) and previous intestinal resection were significantly associated with intra-abdominal sepsis. Both risk factors remained significant on multivariable analysis (OR for triple immunosuppression (vs none) = 3.53 (95% CI, 1.27–9.84); previous intestinal resection OR = 2.27 (95% CI, 1.25–4.13)). A significant trend was seen between an increasing number of these risk factors (triple immunosuppression and previous intestinal resection) and rate of intra-abdominal sepsis (5%, 12%, and 22% for 0, 1, and 2 risk factors; p < 0.01). A trend was observed between increasing number of previous intestinal resections and the rate of intra-abdominal sepsis (p < 0.01). LIMITATIONS: This study is limited by its single-institution tertiary referral center scope. CONCLUSIONS: Combination immunosuppression and previous intestinal resection were both associated with the development of intra-abdominal sepsis. In light of these results, surgeons should consider the effects of combination immunosuppression and a history of previous intestinal resection, in addition to other risk factors, when deciding which patients warrant temporary intestinal diversion. See Video Abstract at http://links.lww.com/DCR/A664.

1 February 2021 in The American Journal of Surgery
Verified
Journal Article
Closed access
ASAlaa Sada
Alaa Sada
AGAmy E. Glasgow
Amy E. Glasgow
BDBenzon M. Dy
Benzon M. Dy
MLMelanie L. Lyden
Melanie L. Lyden
GTGeoffrey B. Thompson
Geoffrey B. Thompson
EHElizabeth B. Habermann
Elizabeth B. Habermann

29 October 2022 in Surgery
Verified
Journal Article
Closed access
MPMara A. Piltin
Mara A. Piltin
AGAmy E. Glasgow
Amy E. Glasgow
EHElizabeth B. Habermann
Elizabeth B. Habermann
THTina J. Hieken
Tina J. Hieken

25 April 2025 in Journal of Bone and Joint Surgery
Verified
Journal Article
Closed access
XCXiao Chen
Xiao Chen
AGAmy E. Glasgow
Amy E. Glasgow
EHElizabeth B. Habermann
Elizabeth B. Habermann
NHNathanael D. Heckmann
Nathanael D. Heckmann
JCJohn J. Callaghan
John J. Callaghan
NBNicholas Anthony Bedard
Nicholas Anthony Bedard
Background: Traditional Medicare (TM) claims data are widely used by researchers and registries to report survivorship following total knee arthroplasty (TKA). The purpose of the present study was to investigate whether the mass exodus of patients from TM to Medicare Advantage (MA) has compromised the fidelity of TM data. Methods: We identified 11,717 Medicare-eligible patients (15,282 knees) who had undergone primary TKA from 2000 to 2020 at a single institution. Insurance type was analyzed, and 84% of TKAs were covered by TM. The rates of survivorship free from revision or reoperation were calculated for patients with TM coverage. The same survivorship end points were recalculated after censoring of patients who transitioned to MA after primary TKA, thereby modeling the impact of losing patients from the TM dataset. Differences in survivorship were compared. The mean duration of follow-up was 10 years. Results: From 2000 to 2020, there was a decrease in TM insurance (from 94% to 68%) and a corresponding increase in MA insurance (from 0% to 19%) among patients undergoing TKA. Following TKA, 25% of patients with TM coverage switched to MA. For patients with TM at the time of surgery, the 15-year rates of survivorship free from any reoperation or revision were 90% and 96%, respectively. When patients were censored upon transition from TM to MA, the 15-year rates of survivorship free from any reoperation (92% versus 90%; hazard ratio [HR] = 1.2; p = 0.001) or any revision (97% versus 96%; HR = 1.3; p = 0.002) were significantly higher. Conclusions: One in 4 patients left TM for MA after primary TKA, effectively making them lost to follow-up within TM datasets. The mass exodus of patients out of TM resulted in falsely elevated estimates of survivorship free from reoperation and from revision, with increasing divergence in survivorship over time, when MA data were excluded. As MA continues to grow, efforts to incorporate these data will become increasingly important. Level of Evidence: Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.

1 May 2021 in JACC
Verified
Journal Article
Closed access
VKVinayak Kumar
Vinayak Kumar
MRMargaret M. Redfield
Margaret M. Redfield
AGAmy E. Glasgow
Amy E. Glasgow
VRVeronique L. Roger
Veronique L. Roger
SWSusan A. Weston
Susan A. Weston
SDShannon Dunlay
Shannon Dunlay